Table 3. Sensitivity analyses for association between statins, β-blockers and low-dose aspirin use and cancer-specific mortality in endometrial cancer patients.

Analysis	Cancer-specific deaths	All patients	Person years	Adjusteda HR (95% CI)	P
Statins
Main analysis: user vs non-user after diagnosis	394	3058	15 653	0.83 (0.64, 1.08)	0.07
Sub group analyses: user vs non-user after diagnosis, restricted to
BMI before diagnosis, ⩽25 kg m−2	68	545	2970	0.75 (0.36, 1.58)	0.46
BMI before diagnosis, 25–<30 kg m−2	97	726	3730	0.80 (0.47, 1.39)	0.43
BMI before diagnosis, >30 kg m−2	141	1144	5606	0.97 (0.63, 1.49)	0.89
Sensitivity analyses: user vs non-user after diagnosis
Stage at diagnosis available (and adjusted for)b	163	1530	7281	0.98 (0.67, 1.46)	0.96
Increasing lag to 1 yearc	394	3058	15 653	0.88 (0.67, 1.16)	0.36
Excluding patients with ⩽6 months follow-up after diagnosisd	523	3306	17 249	0.88 (0.69, 1.11)	0.28
β-Blockers
Main analysis: user vs non-user after diagnosis	394	3058	15 653	0.87 (0.68, 1.10)	0.24
Sub group analyses: user vs non-user after diagnosis, restricted to
BMI before diagnosis, ⩽25 kg m−2	68	545	2970	0.97 (0.48, 1.94)	0.93
BMI before diagnosis, 25–<30 kg m−2	97	726	3730	1.16 (0.72, 1.87)	0.55
BMI before diagnosis, >30 kg m−2	141	1144	5606	0.69 (0.45, 1.04)	0.07
Sensitivity analyses: user vs non-user after diagnosis
Stage at diagnosis available (and adjusted for)b	163	1530	7281	0.88 (0.60, 1.29)	0.51
Increasing lag to 1 yearc	394	3058	15 653	0.91 (0.71, 1.16)	0.43
Excluding patients with ⩽6 months follow-up after diagnosisd	523	3306	17 249	0.83 (0.67, 1.03)	0.10
Low-dose aspirin
Main analysis: user vs non-user after diagnosis	394	3058	15 653	0.91 (0.69, 1.20)	0.52
Sub group analyses: user vs non-user after diagnosis, restricted to
BMI before diagnosis, ⩽25 kg m−2	68	545	2970	0.95 (0.47, 1.89)	0.88
BMI before diagnosis, 25–<30 kg m−2	97	726	3730	0.62 (0.33, 1.16)	0.13
BMI before diagnosis, >30 kg m−2	141	1144	5606	0.75 (0.47, 1.21)	0.24
Sensitivity analyses: user vs non-user after diagnosis
Stage at diagnosis available (and adjusted for)b	163	1530	7281	0.93 (0.61, 1.41)	0.72
Increasing lag to 1 yearc	394	3058	15 653	0.90 (0.68, 1.20)	0.47
Excluding patients with ⩽6 months follow-up after diagnosisd	523	3306	17 249	0.98 (0.77, 1.25)	0.90

Abbreviations: BMI=body mass index; CI=confidence interval; HR=hazard ratio.

^aAdjusted for year of diagnosis, age at diagnosis, surgery within 6 months, radiotherapy within 6 months, chemotherapy within 6 months, deprivation (in fifths), comorbidities (before diagnosis, including cerebrovascular disease, chronic pulmonary disease, congestive heart disease, diabetes, myocardial infarction, peptic ulcer disease, peripheral vascular disease and renal disease), medication use after diagnosis (time varying, including statins, β-blockers and low-dose aspirin).

^bAdjusted model contains all variables in a along with stage at diagnosis (in individuals with stage available).

^cIncreasing lag to 1 year among individuals living more than 1 year after cancer diagnosis.

^dExcluding patients with ≤6 months follow-up after diagnosis with cases followed from 6 months after diagnosis